In AD, phosphatase activity is markedly reduced, particularly PP2A, which shows decreased expression, inhibition, and altered regulation, thereby failing to counterbalance kinase hyperactivity and shifting the balance towards pathological tau phosphorylation [210]. This evidence concerns the gene MAPT and Alzheimer disease.